Netarsudil ophthalmic solution 0.02% + Artificial tears
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma or Ocular Hypertension
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Trial Timeline
Jun 27, 2025 → Apr 1, 2026
NCT ID
NCT06865144About Netarsudil ophthalmic solution 0.02% + Artificial tears
Netarsudil ophthalmic solution 0.02% + Artificial tears is a approved stage product being developed by Novartis for Primary Open Angle Glaucoma or Ocular Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06865144. Target conditions include Primary Open Angle Glaucoma or Ocular Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Primary Open Angle Glaucoma or Ocular Hypertension were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06865144 | Approved | Recruiting |
Competing Products
20 competing products in Primary Open Angle Glaucoma or Ocular Hypertension